{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,2,21]],"date-time":"2025-02-21T18:31:15Z","timestamp":1740162675419,"version":"3.37.3"},"reference-count":23,"publisher":"BMJ","issue":"11","license":[{"start":{"date-parts":[[2022,11,14]],"date-time":"2022-11-14T00:00:00Z","timestamp":1668384000000},"content-version":"unspecified","delay-in-days":13,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100000925","name":"National Health and Medical Research Council","doi-asserted-by":"publisher","award":["Investigator Grant APP1194576"],"award-info":[{"award-number":["Investigator Grant APP1194576"]}],"id":[{"id":"10.13039\/501100000925","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["bmj.com"],"crossmark-restriction":true},"short-container-title":["BMJ Open"],"published-print":{"date-parts":[[2022,11]]},"abstract":"<jats:sec><jats:title>Objectives<\/jats:title><jats:p>Primary aldosteronism (PA), the most common endocrine cause of hypertension, is associated with a higher risk of cardiovascular disease (CVD) than blood pressure (BP)-matched essential hypertension (EH). We aimed to compare the calculated risks of CVD in patients who had hypertension with PA or EH using CVD risk calculators, hypothesising that they will fail to recognise the increased CVD risk in PA.<\/jats:p><\/jats:sec><jats:sec><jats:title>Design<\/jats:title><jats:p>Cross-sectional analysis.<\/jats:p><\/jats:sec><jats:sec><jats:title>Setting<\/jats:title><jats:p>An endocrine hypertension service in Victoria, Australia.<\/jats:p><\/jats:sec><jats:sec><jats:title>Participants<\/jats:title><jats:p>Patients who had hypertension without CVD referred for the investigation of hypertension.<\/jats:p><\/jats:sec><jats:sec><jats:title>Outcome measures<\/jats:title><jats:p>Calculated 5-year or 10-year CVD risk as predicted by the National Vascular Disease Prevention Alliance (NVDPA) algorithm, Framingham Risk Score, Pooled Cohort Equations and QRISK3.<\/jats:p><\/jats:sec><jats:sec><jats:title>Results<\/jats:title><jats:p>Those with PA (n=128) and EH (n=133), did not differ significantly in their calculated CVD risks with the NVDPA algorithm (moderate-to-high 5-year risk 36\/100 vs 45\/99, p=0.17); the Framingham Risk Score (median 10-year risk 7.72% (4.43%\u201312.95%) vs 6.84% (3.85%\u201310.50%), p=0.14); the Pooled Cohort Equations (median 10-year risk 9.45% (4.36%\u201315.37%) vs 7.90% (2.09%\u201314.73%), p=0.07); and QRISK3 (median 10-year risk 11.31% (7.22%\u201320.29%) vs 12.47% (5.10%\u201319.93%), p=0.51). Similarities persisted on regression analyses accounting for systolic BP.<\/jats:p><\/jats:sec><jats:sec><jats:title>Conclusions<\/jats:title><jats:p>CVD risk algorithms do not reflect the increased risk of CVD in patients with PA, and likely underestimate the true risk of CVD among those with PA. Screening for PA, in addition to using the CVD risk algorithm in patients who had hypertension, may facilitate the targeted treatment of PA and minimisation of cardiovascular risk in affected individuals.<\/jats:p><\/jats:sec>","DOI":"10.1136\/bmjopen-2022-062406","type":"journal-article","created":{"date-parts":[[2022,11,14]],"date-time":"2022-11-14T17:02:26Z","timestamp":1668445346000},"page":"e062406","update-policy":"https:\/\/doi.org\/10.1136\/crossmarkpolicy","source":"Crossref","is-referenced-by-count":1,"title":["Risky business: a single-centre cross-sectional analysis of calculated cardiovascular risk in patients with primary aldosteronism and essential hypertension"],"prefix":"10.1136","volume":"12","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-5868-3962","authenticated-orcid":false,"given":"Pravik","family":"Solanki","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Stella May","family":"Gwini","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Renata","family":"Libianto","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Genevieve","family":"Gabb","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jimmy","family":"Shen","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Morag J","family":"Young","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Peter J","family":"Fuller","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jun","family":"Yang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"239","published-online":{"date-parts":[[2022,11,14]]},"reference":[{"key":"2022111409003987000_12.11.e062406.1","doi-asserted-by":"crossref","first-page":"1467","DOI":"10.1016\/S0140-6736(21)02144-9","article-title":"World heart day 2021: COVID-19, digital health, and tackling cardiovascular disease","volume":"398","author":"Pinto","year":"2021","journal-title":"Lancet"},{"key":"2022111409003987000_12.11.e062406.2","unstructured":"National Vascular Disease Prevention Alliance . Guidelines for the management of absolute cardiovascular disease risk. Australia, 2012."},{"key":"2022111409003987000_12.11.e062406.3","doi-asserted-by":"publisher","DOI":"10.1161\/01.CIR.97.18.1837"},{"key":"2022111409003987000_12.11.e062406.4","unstructured":"National Heart, Lung, and Blood Institute . Assessing cardiovascular risk: systematic evidence review from the risk assessment work group. United States: National Institutes of Health, 2013."},{"key":"2022111409003987000_12.11.e062406.5","unstructured":"ClinRisk . QRISK3, 2018. Available: https:\/\/qrisk.org\/three\/index.php"},{"key":"2022111409003987000_12.11.e062406.6","doi-asserted-by":"crossref","first-page":"41","DOI":"10.1016\/S2213-8587(17)30319-4","article-title":"Cardiovascular events and target organ damage in primary aldosteronism compared with essential hypertension: a systematic review and meta-analysis","volume":"6","author":"Monticone","year":"2018","journal-title":"Lancet Diabetes Endocrinol"},{"key":"2022111409003987000_12.11.e062406.7","doi-asserted-by":"publisher","DOI":"10.1210\/jc.2016-1472"},{"key":"2022111409003987000_12.11.e062406.8","doi-asserted-by":"publisher","DOI":"10.7326\/M20-0065"},{"key":"2022111409003987000_12.11.e062406.9","doi-asserted-by":"crossref","first-page":"973","DOI":"10.1055\/s-0035-1565124","article-title":"Cardiovascular risk in primary hyperaldosteronism","volume":"47","author":"Prejbisz","year":"2015","journal-title":"Horm Metab Res"},{"key":"2022111409003987000_12.11.e062406.10","doi-asserted-by":"crossref","first-page":"46","DOI":"10.1016\/j.ijcard.2016.01.200","article-title":"Cardiovascular risk markers in patients with primary aldosteronism: a systematic review and meta-analysis of literature studies","volume":"208","author":"Ambrosino","year":"2016","journal-title":"Int J Cardiol"},{"key":"2022111409003987000_12.11.e062406.11","doi-asserted-by":"crossref","first-page":"411","DOI":"10.1161\/HYPERTENSIONAHA.121.17436","article-title":"Renal injuries in primary aldosteronism: quantitative histopathological analysis of 19 patients with primary Adosteronism","volume":"78","author":"Ogata","year":"2021","journal-title":"Hypertension"},{"key":"2022111409003987000_12.11.e062406.12","doi-asserted-by":"crossref","first-page":"459","DOI":"10.1055\/a-1120-8623","article-title":"Primary aldosteronism: where are we now? where to from here?","volume":"52","author":"Funder","year":"2020","journal-title":"Horm Metab Res"},{"key":"2022111409003987000_12.11.e062406.13","doi-asserted-by":"publisher","DOI":"10.1210\/jc.2015-4061"},{"key":"2022111409003987000_12.11.e062406.14","doi-asserted-by":"crossref","first-page":"51","DOI":"10.1016\/S2213-8587(17)30367-4","article-title":"Cardiometabolic outcomes and mortality in medically treated primary aldosteronism: a retrospective cohort study","volume":"6","author":"Hundemer","year":"2018","journal-title":"Lancet Diabetes Endocrinol"},{"key":"2022111409003987000_12.11.e062406.15","doi-asserted-by":"crossref","first-page":"478","DOI":"10.1038\/s41371-020-0336-2","article-title":"Primary aldosteronism is a public health issue: challenges and opportunities","volume":"34","author":"Libianto","year":"2020","journal-title":"J Hum Hypertens"},{"key":"2022111409003987000_12.11.e062406.16","doi-asserted-by":"crossref","first-page":"254","DOI":"10.5694\/j.1326-5377.2010.tb03502.x","article-title":"Cardiovascular risk perception and evidence--practice gaps in Australian general practice (the AusHEART study)","volume":"192","author":"Heeley","year":"2010","journal-title":"Med J Aust"},{"key":"2022111409003987000_12.11.e062406.17","doi-asserted-by":"crossref","DOI":"10.1186\/s12875-016-0499-7","article-title":"Factors influencing general practitioners' decisions about cardiovascular disease risk reassessment: findings from experimental and interview studies","volume":"17","author":"McKinn","year":"2016","journal-title":"BMC Fam Pract"},{"key":"2022111409003987000_12.11.e062406.18","doi-asserted-by":"crossref","first-page":"382","DOI":"10.3390\/jcm7110382","article-title":"Plasma aldosterone concentration as a determinant for statin use among middle-aged hypertensive patients for atherosclerotic cardiovascular disease","volume":"7","author":"Lin","year":"2018","journal-title":"J Clin Med"},{"key":"2022111409003987000_12.11.e062406.19","doi-asserted-by":"publisher","DOI":"10.1136\/bmj.j2099"},{"key":"2022111409003987000_12.11.e062406.20","doi-asserted-by":"publisher","DOI":"10.1016\/0002-8703(91)90861-B"},{"key":"2022111409003987000_12.11.e062406.21","doi-asserted-by":"crossref","first-page":"2139","DOI":"10.12688\/f1000research.21679.1","article-title":"R package \u201cQRISK3\u201d: an unofficial research purposed implementation of ClinRisk\u2019s QRISK3 algorithm into R","volume":"8","author":"Li","year":"2019","journal-title":"F1000Res"},{"key":"2022111409003987000_12.11.e062406.22","doi-asserted-by":"publisher","DOI":"10.1161\/JAHA.121.023082"},{"key":"2022111409003987000_12.11.e062406.23","doi-asserted-by":"crossref","first-page":"1899","DOI":"10.1161\/HYPERTENSIONAHA.122.17964","article-title":"Aldosterone as a mediator of cardiovascular damage","volume":"79","author":"Buffolo","year":"2022","journal-title":"Hypertension"}],"container-title":["BMJ Open"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/syndication.highwire.org\/content\/doi\/10.1136\/bmjopen-2022-062406","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,11,14]],"date-time":"2022-11-14T17:02:38Z","timestamp":1668445358000},"score":1,"resource":{"primary":{"URL":"https:\/\/bmjopen.bmj.com\/lookup\/doi\/10.1136\/bmjopen-2022-062406"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,11]]},"references-count":23,"journal-issue":{"issue":"11","published-online":{"date-parts":[[2022,11,14]]},"published-print":{"date-parts":[[2022,11]]}},"alternative-id":["10.1136\/bmjopen-2022-062406"],"URL":"https:\/\/doi.org\/10.1136\/bmjopen-2022-062406","relation":{},"ISSN":["2044-6055","2044-6055"],"issn-type":[{"type":"print","value":"2044-6055"},{"type":"electronic","value":"2044-6055"}],"subject":[],"published":{"date-parts":[[2022,11]]}}}